Author + information
- Marcos Ortega1,
- Marcelo Medrano2,
- Richard Lopez3,
- Mauricio Navarrete4,
- Jose Llorente4,
- Paulino Quiñonez4 and
- J. Ribamar Costa Jr.5
Safety concerns with 1st generation of bioabsorbable vascular scaffolds(BRShave prompted the development of next generation of these devices, focused on thinner struts and faster resorption time. Recently developed, the MeRes100 (Meril Life Sciences) is a sirolimus-eluting (1.25 μg/mm2) BRS, which is built of a thin-strut (100μm) PLLA polymer with a hybrid cell design (closed cells on the edges and open cells on the center). There are couplets of tri-axial radiopaque markets at either end to facilitate scaffold positioning and post dilation. Bioresorption is expected to occur within 2 years.We sought to evaluate the performance of this device in the treatment of “real-world”, less selected patients.
A propective, single center registry including patients treated between August 2016 and June 2017. Exclusion criteria were: cardiogenic shock, in stent restenosis and target lesions at left main/bypass graft. BRS were available in 2.5 to 3.5m and up to 40mm in length. All procedures were guided by OCT. Primary endpoints included procedure success and one-year MACE rate. Nine-month OCT assessment is part of the secondary endpoints.
A total of 34 patients underwent PCI with 41 MeRes100. Most patients were male (87%), with mean age of 66yo and 45% of diabetes. Non ST elevation MI was the initial clinical presentation in 30% of the cases, while LAD was the most frequent target vessel (44%). Device success was achieved in 97% of the cases. In the hospital phase, MACE rate was 0%. During the clinical follow-up period, a single case of BRS thrombosis was observed, in a patient who discontinued DAPT in the 1st month after the procedure.
Preliminary results of this experience showed a excellent acute performance of this novel thin-strut BRS. Late clinical follow up combined with 9-month OCT evaluation will add important information on this novel device.
CORONARY: Stents: Bioresorbable Vascular Scaffolds